MBX Biosciences raises $163.2 mln in US IPO
Updates with further details in paragraph 3-11
Sept 12 (Reuters) -MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering.
The biotechnology company priced its offering of 10.2 million shares at $16 apiece, at the high-end of its targeted range of $14 to $16 each.
The IPO valued the company at $482.5 million.
Newer weight-loss drugs, such as EliLilly's LLY.NZepbound and Novo Nordisk's NOVOb.CO Wegovy, have caught the investors' attentionafter proving to be an effective obesity treatment and showing potential to reduce stroke or heart attackrisks.
The sector's enthusiasm could boostthe IPO-bound company as the broader market for new issues has been sluggish despitehopes of a meaningful recovery.
Wall Street estimates annual global sales of $150 billion for weight-loss drugs by the early 2030s.
MBX's lead experimental candidate, MBX 2109, is being developed to treat chronic hypoparathyroidism — a condition in which the body produces insufficient levels of parathyroid hormone that disrupts calcium levels in the blood and bones.
The company is also developing MBX 4291, an experimental therapy for the treatment of obesity. The therapy mimics the effect of two gut hormones, GLP-1 and GIP, and is currently in preclinical development.
Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro for diabetes in the U.S., also mimics the function of these two gut hormones.
MBX will be listed on the Nasdaq Global Select Market under the ticker symbol"MBX".
J.P.Morgan, Jefferies, Stifel and Guggenheim Securities are underwriting the offering.
Reporting by Manya Saini and Devika Nair in Bengaluru; Editing by Shilpi Majumdar and Alan Barona
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
